PhRMA president and CEO Stephen J. Ubl joined Fox Business’ Maria Bartiromo on “Mornings with Maria” today to discuss bold steps the biopharmaceutical industry has taken in the last few months as part of its commitment to advance a multifaceted solution to address the opioid crisis. Most recently, PhRMA announced its support for policies limiting the supply of opioids to seven days for acute pain treatment.
PhRMA has also been working closely with the President’s Commission on Combating Drug Addiction and the Opioid Crisis, the National Institutes of Health (NIH) and the Food and Drug Administration to develop a public-private partnership that will accelerate the development of non-opioid, non-addictive pain medicines and medication-assisted treatments for long-term addiction recovery. The public-private partnership would allow increased information sharing and collaboration between government and industry to speed the drug development process.
Holly Campbell
Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines.
Holly Campbell
Mass compounding puts patients at risk
CMS’ MFN proposals won’t help seniors despite lofty promises
Voters voice concerns on government price controls
Advancing patient care: A look at new medicines approved in 2025
Knockoffs of FDA-approved drugs put patients at risk
PDUFA: Essential to America’s edge in drug development and patient access
Major drug compounder is spending millions on misleading Super Bowl ad
More oversight needed of unapproved medicines that threaten patients’ health
The use of real-world data in drug development
New analysis: Accelerated approval pathway is changing lives in underserved communities
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
Florida’s importation plan puts patients in danger
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
Decentralized clinical trials and the future of drug development
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
How FDA’s modernization strategy could improve drug development
Setting the record straight on accelerated approval
FDA should remain the authority on the safety and effectiveness of medicines
Recognizing National Glaucoma Awareness Month
What you should know about real-world evidence and drug development
In their own words: Insured Americans support policy reforms that address access and affordability concerns
Three things to know about the accelerated approval pathway
PDUFA and BsUFA reauthorizations are wins for patients
Navigating the patient experience: Burdens and barriers standing between patients and their care
This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy
Myth vs. Fact: The Senate’s latest price setting proposal
ICYMI: Patients across the country are sharing concerns about government price setting
New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
The Patient Perspective: Government price-setting harms patients
Word of the Month: Biomarkers and surrogate endpoints
Why drug importation is bad for Americans
Ensuring timely reauthorization of PDUFA and BsUFA
Spotlighting a growing mental health challenge
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
The importance of timely PDUFA and BsUFA reauthorization
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition
Meeting Tomorrow: Looking ahead to PDUFA VII
The impact of monoclonal antibodies and COVID-19 recovery
PDUFA VII is critical for future biopharmaceutical innovation and for patients
How strengthening the biosimilar marketplace benefits patients
The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
Getting the 340B program back on track in 2021
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Nearly 400 cell and gene therapies in development to target a broad range of diseases
PhRMA submits comments on FDA’s proposed rule on drug importation
Drug importation: An old idea that is still a bad idea
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
What they’re saying: Safety is top concern for recent drug importation proposal
ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals
PhRMA responds to Florida’s request for information on drug importation
Guest Post: Using the patient voice to go boldly
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
PhRMA CEO raises concerns with Florida importation proposal, highlights reforms needed to lower costs for patients
Guest post: Hearing from patients on Rare Disease Day
Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation
Look at the facts. Drug importation is dangerous.
Why state drug importation pilot programs don’t work
PhRMA comments to administration on Medicare Part D proposed rule
Putting 2018 medicine approvals in context
Keep the Six Protected Classes, protected
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
Balancing innovation and competition in the biologics marketplace
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
How much do you know about Medicare Part B?
How ICER’s assessment of a new class of migraine treatments fails patients
New analysis shows that more medicines worldwide are available to U.S. patients
New 340B analysis: Hospitals raking in billions while uncompensated care drops by billions
Securely dispose of your unwanted medicines on National Take Back Day
Spending on medicines grew less than one percent in 2017
New report shows over 500 medicines in development for neurological disorders
Rare Disease Day: Unmet need inspires innovation
Innovation comes in many forms, including new and expanded uses of existing medicines
Fact Check Friday: The truth about the cost of 340B to patients
340B Spotlight: New pieces of legislation continue momentum to fix 340B program
ICYMI: Why 2017 medicine approvals matter
New surveys find payers and providers want more data from biopharmaceutical companies
Supporting opportunities for enhanced competition in the marketplace
340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform
The Washington Post retracts PhRMA claim in opioid story
PhRMA response to Washington Post and 60 Minutes stories
Protect your health: Important disaster preparedness tips for Harvey and Irma
PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis
Opportunities to build upon enhanced competition for medicines in the marketplace
Why reauthorization of PDUFA matters
A critical opportunity to prevent prescription drug abuse
Former law enforcement officials raise concerns with drug importation proposals
Resources for understanding the dangers of drug importation
Medicare Monday: A discussion on affordability and access to medicines
17 years (and more) of medical discoveries
Guest Post: The importance of a modern FDA in drug discovery
How drug importation schemes could increase U.S. law enforcement burdens
Case Study: How one online pharmacy knowingly endangered U.S. consumers
Why drug importation threatens patient safety
Fact Check Friday: The truth about drug importation and patient safety
How do multiple sclerosis patients define value?
ICYMI: New era of medicine initiative kicks off in Boston
What you don’t know about importation from Canada
Biopharmaceutical industry’s success reducing disparities for African Americans
Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
FDA
Patients
Prescription Drug Safety
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria